NCT00831987View on ClinicalTrials.gov

Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 28, 2006

Study Completion Date

February 28, 2006

Conditions
Influenza
Interventions
BIOLOGICAL

Fluzone®: Influenza virus vaccine 2004-2005 formulation

0.5 mL, Intramuscular

BIOLOGICAL

Fluzone®: Influenza virus vaccine 2004-2005 formulation

0.5 mL, Intramuscular

Trial Locations (1)

23507

Norfolk

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT00831987 - Safety and Immunogenicity of the World Health Organization (WHO) Formulation of the 2004-2005 Fluzone® Vaccine | Biotech Hunter | Biotech Hunter